Please join for an Open Scientific Discussion (OSD) hosted by the AAPS Biomarkers and Precision Medicine (BPM) Community on October 2nd, 12 – 1 pm EST on the following topic:
Considerations for Biomarker Strategy Implementation in a Drug Development Program (Part 1)
- When and how do you start setting biomarker strategy? What is the team composition?
- How does strategy change as a drug progresses through development?
- Brief overview of the types of biomarkers and Context of Use
- Perspective and approaches from different companies
Discussion Leaders:
- Lakshmi Amaravadi (AstraZeneca)
- Michele Gunsior (Astria Therapeutics)
- Christopher Stroh (Merck Healthcare KGaA)
Organized by: Karen Quadrini (Prothena Biosciences), Carmen Fernández-Metzler (PharmaCadence), Kyra Cowan (Merck Healthcare KGaA)
We start at 12:00 EST sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.
(Please remain on mute unless asking questions)
When: Wednesday, Oct. 2, 2024 12pm – 1pm EST
Where: Please join from your computer, tablet or smartphone.
https://global.gotomeeting.com/join/305789893
You can also dial in using your phone.
United States: +1 (872) 240-3412
Access Code: 305-789-893
Join from a video-conferencing room or system.
Dial in or type: 67.217.95.2 or inroomlink.goto.com
Meeting ID: 305 789 893
Or dial directly: [email protected] or 67.217.95.2##305789893
New to GoToMeeting? Get the app now and be ready when your first meeting starts:
https://global.gotomeeting.com/install/305789893
Please feel free to share with colleagues who may be interested in this topic.
Thanks,
On Behalf of The AAPS Biomarkers and Precision Medicine Community Leadership Team
------------------------------
Carmen Fernandez-Metzler Ph.D.
President
PharmaCadence Analytical Services, LLC
Hatfield PA
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------